



- (51) **International Patent Classification:**
A61K 39/12 (2006.01) *C07K 14/18* (2006.01)
- (21) **International Application Number:**
PCT/GB2018/052698
- (22) **International Filing Date:**
21 September 2018 (21.09.2018)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/561,234 21 September 2017 (21.09.2017) US
- (71) **Applicant: EMERGEX VACCINES HOLDING LIMITED** [GB/GB]; 4 & 5 Dunmore Court, Wootton Road, Abingdon Oxfordshire OX13 6BH (GB).
- (72) **Inventor: PHILIP, Ramila;** 115 Golfview Drive, Ivyland, Pennsylvania 18974 (US).
- (74) **Agent: TUXWORTH, Pamela Mary;** J A Kemp, 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,


DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

- (54) **Title:** MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus

Fig. 1

- (57) **Abstract:** The invention provides a vaccine composition comprising a flavivirus peptide comprising one or more CD8⁺ T cell epitopes, wherein the peptide is attached to a nanoparticle.